Signals mentioning Mamaearth
- Honasa buys 58% of Fluence Pharma at ₹135 cr EV, enters ₹16,000-cr nutraceuticals via Honasa Health
- Honasa Buys 58% of Fluence Pharma for Rs 135 Cr, Launches Honasa Health for Nutraceuticals
- Honasa Consumer acquires 58% of Fluence Pharma at Rs 135 cr EV, launches Honasa Health subsidiary
- Honasa Buys 58% Of Fluence Pharma, Pushes Mamaearth Into Beauty-From-Within
- Honasa buys 58% of Fluence Pharma for ₹135 Cr, enters nutraceuticals via Honasa Health
- Honasa buys 58% of Fluence Pharma at ₹135 cr EV, enters ₹16,000 cr nutraceuticals market
- Honasa buys 58% of Fluence Pharma at ₹135 cr EV, enters ₹16,000-cr nutraceuticals category
- Honasa Consumer to acquire 58% of Fluence Pharma at Rs 135 cr EV, enters Rs 16,000 cr supplements market
- Honasa buys 58% of Fluence Pharma for Rs 135 Cr, launches Honasa Health for nutraceuticals push
- Honasa buys 58% of Fluence Pharma for Rs 135 Cr, launches Honasa Health for D2C wellness play
- Honasa Buys 58% of Fluence Pharma for ₹135 Cr, Launches Honasa Health for Nutraceuticals
- AI flattens marketing into 'intelligent sameness'; Zomato's voice held up as D2C survival blueprint
- Myntra EORS pulls 1.3X first-time shoppers, with 55% demand from non-metros
- FMCG distribution moat erodes as ONDC, quick commerce flatten route-to-market
- L'Oreal to acquire majority stake in Indian BPC roll-up Innovist
- Honasa hires Richa Gupta as SVP to run ecommerce across marketplaces and quick commerce
- RAI's Bhatt flags D2C consolidation, quick commerce, AI as North East retail eyes scale
- Lenskart slips 2.4% on ADIA ₹1,960 Cr exit; Honasa hits 52-week high on FY31 ₹5,500 Cr plan
- Indian startups raise $255.9M; ADIA exits Lenskart stake, Zepto files Rs 8,010 Cr IPO
- Honasa eyes ₹5,500 cr by FY31 as Q4 revenue jumps 23% and margins recover